Testing a new drug for advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 trial studies QLP2117, a new treatment, in people with advanced solid tumors that have come back or didn’t respond to standard care. It mainly looks at safety and how the body handles the drug, and it may help find a dose worth further study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer that is getting worse despite treatment, or you can’t tolerate standard treatment, or there’s no standard option
- You have at least one tumor spot the doctors can measure on scans (or it can be assessed for this study)
- You are able to do daily activities fairly well (performance status 0 or 1)
- You can share saved tumor tissue from a previous biopsy or surgery
- Blood test and organ test results are good enough for treatment (kidneys, liver, and others per the study rules)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.
This Phase 1 trial tests the safety and how the medicine works in the body, and also looks at early signs of effectiveness. It is for adults with advanced solid tumors, and for Phase 1b specifically, the tumor must show a marker called GPC3.
This trial tests a new drug called QLM2011 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.